PRINCETON, NJ--(Marketwire - Aug 11, 2011) - Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women's contraceptive products, today announced that it has been named, "Life Sciences Company of the Year," by the New Jersey Technology Council (NJTC), a not-for-profit organization supporting growth in New Jersey's various technology sectors, including health sciences.

The NJTC received more than 100 nominations for Gala Awards. Agile was selected as the Life Science Company of the Year based upon the following criteria:

  • Impact on industry
  • Growth rate faster than competitors
  • Contribution to industry standards
  • Success in marketplace

"We are honored to receive this recognition from the New Jersey Technology Council. Being named the 2011 Life Sciences Company of the Year by this prestigious organization is a testament to the hard work and dedication of the entire Agile team to develop more convenient contraceptive options for women," said Al Altomari, President and CEO of Agile Therapeutics Inc. "We hope to continue to make an impact as we enter the final stages of making AG200-15, our contraceptive patch, available to women who seek convenient contraceptive options. We initiated our phase 3 clinical trials with AG200-15 last August, and completion is expected by the end of 2011."

Agile Therapeutics will receive the award on November 17, 2011, at a black-tie gala being held by NJTC at The Addison Park in Aberdeen, NJ. The NJTC Gala Awards is held annually to publicly recognize and celebrate some of New Jersey's upcoming and most successful organizations. The awards gala will highlight the Company of the Year winners in the fields of software, life science, electronics, communications, energy and nanotechnology as well as several individual awards.

About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company's lead product, AG200-15, is a once-weekly contraceptive patch currently in Phase III clinical trials. In addition, Agile is also developing a low-dose, progestin-only contraceptive patch, AG900. Both AG200-15 and AG900 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit

About the New Jersey Technology Council
The New Jersey Technology Council provides business support, networking opportunities, information, advocacy and recognition of technology companies and their leaders. Founded in 1996, NJTC's almost 1,000 member companies work together to support their own enterprises while advancing New Jersey's status as a leading technology center in the United States.

Contact Information:

Laura Yoshida for Agile Therapeutics